| Bid | 3.36 |
| Market Cap | 230.24M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -1.54 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.12 |
| Volume | 1,099,484 |
| Avg. Volume (20D) | 1,047,914 |
| Open | 3.45 |
| Previous Close | 3.37 |
| Day's Range | 3.29 - 3.49 |
| 52-Week Range | 3.17 - 12.75 |
| Beta | undefined |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu...
Analyst Forecast
According to 6 analyst ratings, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 791.53% from the latest price.
4 weeks ago · businesswire.com
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...
2 months ago · businesswire.com
Compass Pathways Announces Third Quarter 2024 Financial Results and Business UpdatesLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental ...
2 months ago · businesswire.com
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024LONDON--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announc...